Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03311009 · ClinicalTrials.gov registry record · Phase 1

A Study With GLPG1972 in Osteoarthritis Subjects

A Phase 1 study of Osteoarthritis, sponsored by Galapagos.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT03311009 is a Phase 1 study of Osteoarthritis that has completed, run by Galapagos. The registered enrollment target is 30 participants, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03311009, a Phase 1 study of Osteoarthritis, has completed, sponsored by Galapagos.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo. Per cohort, 10 subjects will be randomized in a 4:1 allocation ratio to active treatment with GLPG1972 or matching placebo. In each cohort, OA subjects will be stratified for age (50- 64 years and 65-75 years) with a minimum of 2 of each sex per age group.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG GLPG1972 cohort 1
  • DRUG GLPG1972 cohort 2
  • DRUG GLPG1972 cohort 3

Study Locations (1)

Florida

  • Covance Daytona Beach - Daytona Beach

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-05-15
Est. Completion 2017-10-25
Phase Phase 1

Sponsor

Galapagos

7 total trials

What the Registry Record Tells You About NCT03311009

The ClinicalTrials.gov registry entry for NCT03311009 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (96% lower). The listed sponsor is Galapagos, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT03311009 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03311009 about?

NCT03311009 is a clinical study titled "A Study With GLPG1972 in Osteoarthritis Subjects". This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo. Per cohort, 10 subjects will be randomized...

What is the current status of trial NCT03311009?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-05-15. Estimated completion is 2017-10-25.

What conditions does trial NCT03311009 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT03311009?

The interventions under investigation include: Placebo (DRUG), GLPG1972 cohort 1 (DRUG), GLPG1972 cohort 2 (DRUG), GLPG1972 cohort 3 (DRUG).

Who is sponsoring clinical trial NCT03311009?

This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03311009 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.